Study opens new prospects for developing new targeted therapies for breast cancer

5th IMPAKT Breast Cancer Conference

2013-05-02

(Press-News.org) Lugano-CH, Brussels-BE, 2 May 2013 -- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients. This current study was led by Dr Martine Piccart, Director of Medicine at the Jules Bordet Institute in Brussels, and Dr Jose Baselga, Associate Director at Memorial Sloan-Kettering Cancer Center, New York. The researchers used modern sequencing technology to characterise the genetic aberrations of cancer genes present in tumour samples from a well-defined cohort of advanced postmenopausal patients who were enrolled in the BOLERO-2 clinical trial. "The results of this study generated hypotheses for developing more rational targeted therapy combinations based on the specific genetic aberrations present in each individual tumour," Dr Piccart said. "This work, together with previous works published last year, highlights again the genetic heterogeneity of breast cancer. These results show that tumours that may look very similar at the clinical level, can be genetically very different, suggesting that they may require different treatment strategies." "There is still a long way to go before we will be able to offer truly personalised therapies to cancer patients, and support for research such as this will be critical to accelerate this process," Dr Piccart said. The study involved postmenopausal women with advanced breast cancer that was hormone receptor positive and HER2 negative taking part in the BOLERO-2 phase III trial. The trial showed that everolimus plus exemestane significantly improved progression-free survival, response rate and clinical benefit rate versus placebo plus exemestane. Although benefits were seen in all prospectively defined subgroups of women who took part, the researchers noted some variations, partially due to genetic differences in molecular determinants of everolimus sensitivity and interactions between the oestrogen receptor and mTOR pathways. In the current analysis, researchers used next-generation sequencing to assess genetic alterations in archival tumour specimens from 230 tumours. They analysed coding regions of 182 cancer-related genes for sequence and copy number variations. All patients had at least one genetic alteration, and 98% had more than 2, the researchers report. A total of 173 different genes were altered in at least one of the tumour samples. Among the frequently mutated genes were PIK3CA, TP53 and ARID1A. "Some mutations were found to cluster into similar pathways, for which targeted therapies could potentially be used," Dr Piccart said. "Although in many cases we cannot be sure what effect the mutations have on the tumour characteristics or the clinical efficacy of treatments, we did find that mutations in the tumour suppressor gene PTEN were associated with loss of protein expression and function." The authors also found an increased mutation rate for the oestrogen receptor, a key player in breast cancer, between primary and metastatic samples, which highlights potentially clinically relevant differences between the primary and metastatic disease for this group of hormone-receptor positive patients. More generally, the results illustrate that this kind of sequencing is feasible in phase III studies, the researchers say. "The ability to carry on large-scale sequencing in phase III trials will potentially help us understand why some patients did show a good clinical response to the investigated drugs whereas others did not. Also, being able to sequence cancer genes in well-described clinically homogeneous cohorts of clinical trials will help to build new hypotheses regarding future targeted treatment strategies." Dr Fabrice Andre from the Department of Medical Oncology at Institut Gustave Roussy, Villejuif, France, who was not involved in the research, said the study has two major impacts for clinical research. First, he said, it suggests that next generation sequencing can be applied in the daily practice using archival samples. This opens new avenues for the development of personalised medicine trials. Second, by discovering new genomic segments, this study will certainly lead to the development of new biomarker-driven trials. "This is a pioneering study in the field of personalised therapy for breast cancer since it shows for the first time that next generation sequencing can be applied to 'real-life' samples of patients with breast cancer. Until now, most of the data from next generation sequencing have been obtained with frozen tissue specifically for this purpose," Dr Andre said. "Interestingly, this study, done in patients who have relapsed, shows an increased frequency of mutations in important genes like ESR1, IGF1R. This could lead to the development of new trials testing compounds against these genomic segments," Dr Andre said. Following this study, prospective trials are needed to test whether the use of genomics could improve outcomes for patients, he said. "Also, we still need a comprehensive analysis of metastatic tissue in order to better develop drugs and understand the metastatic phenomenon. These two purposes will be addressed in the large pan-European effort called PRISM and led by Breast International Group (BIG)." ### END

ELSE PRESS RELEASES FROM THIS DATE:

Breast cancer heterogeneity no barrier to predictive testing, study shows

2013-05-02

Lugano-CH, Brussels-BE, 2 May 2013 -- Breast cancers contain many different cell types with different patterns of gene expression, but a new study provides reassurance that this variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients. The findings were reported at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients. In recent years it has become clear that breast ...

Primate hibernation more common than previously thought

2013-05-02

DURHAM, N.C. -- Until recently, the only primate known to hibernate as a survival strategy was a creature called the western fat-tailed dwarf lemur, a tropical tree-dweller from the African island of Madagascar. But it turns out this hibernating lemur isn't alone. In a study appearing May 2 in the journal Scientific Reports, researchers report that two other little-known lemurs -- Crossley's dwarf lemur and Sibree's dwarf lemur -- burrow into the soft, spongy rainforest floor in the eastern part of Madagascar, curl up and spend the next three to seven months snoozing ...

Duke researchers identify gene mutations associated with nearsightedness

2013-05-02

DURHAM, N.C. -- People have long taken for granted that glasses and contact lenses improve vision for nearsightedness, but the genetic factors behind the common condition have remained blurry. Now researchers at Duke Medicine are closer to clearing this up. Mutations in a gene that helps regulate copper and oxygen levels in eye tissue are associated with a severe form of nearsightedness, according to a study published in the American Journal of Human Genetics on May 2, 2013. Nearsightedness – also known as myopia – is the most common human eye disease in the world. ...

New imaging technique to visualize bio-metals and molecules simultaneously

2013-05-02

Metal elements and molecules interact in the body but visualizing them together has always been a challenge. Researchers from the RIKEN Center for Life Science Technologies in Japan have developed a new molecular imaging technology that enables them to visualize bio-metals and bio-molecules simultaneously in a live mouse. This new technology will enable researchers to study the complex interactions between metal elements and molecules in living organisms. Metal elements such as zinc, iron and copper are present in trace amounts in the body and play an important role ...

Scientists revolutionize the creation of genetically altered mice to model human disease

2013-05-02

CAMBRIDGE, Mass. (May 2, 2013) – Whitehead Institute Founding Member Rudolf Jaenisch, who helped transform the study of genetics by creating the first transgenic mouse in 1974, is again revolutionizing how genetically altered animal models are created and perhaps even redefining what species may serve as models. "This new method is a game changer," says Jaenisch, who is also a professor of biology at MIT. "We can now make a mouse with five mutations in just three to four weeks, whereas the conventional way would take three to four years. And it's rather straightforward, ...

Bigger birth weight babies at greater risk of autism

2013-05-02

It is the first time that a clear link has been made between babies who grow to above average size at birth and risk of Autism Spectrum Disorder and follows from a study of more than 40,000 child health records in Sweden. The research, led by The University of Manchester, also confirms earlier research which reported that premature and poorly grown, low weight babies appear more susceptible to the condition. Autism affects how individuals interact with the world and with other people and there is no known cure. One child in 100 has the condition in the UK according ...

No greater death risk for children admitted to emergency out-of-hours intensive care

2013-05-02

Children admitted to UK intensive care units in out-of-hours emergencies are at no greater risk of dying than children arriving during normal working hours, according to new research. However, mortality rates are significantly higher in the winter, even after taking into account added health risks for children in the colder months. The study, published by researchers at the University of Leeds and the University of Leicester in the Journal of Pediatrics, is the first large-scale analysis of the influence of admission times on deaths in paediatric intensive care units. ...

Newly-discovered human fat cell opens up new opportunities for future treatment of obesity

2013-05-02

The body's brown fat cells play a key role in the development of obesity and diabetes. Researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, have now discovered that we humans have two different kinds of brown fat cells and not one kind as previously thought. This discovery, now published in Nature Medicine, opens up new opportunities for future medicines that exploit the brown fat cells' ability to consume calories. Unlike white fat cells, which store the body's surplus energy in the form of fat, brown fat cells have the unique property of being able ...

Exercise proves to be ineffective against care home depression

2013-05-02

Researchers at the University of Warwick and Queen Mary, University of London have shown that exercise is not effective in reducing burden of depression among elderly care home residents. Exercise is a low risk intervention that can improve mental health but the findings of a National Institute for Health Research Health Technology Assessment Programme study, published in The Lancet, conclude that there is a requirement for alternative approaches to reduce the burden of depression in frail, very elderly, care home residents. The large randomised controlled trial sought ...

Stem cell discovery could aid research into new treatments

2013-05-02

Scientists have made a fundamental discovery about how the properties of embryonic stem cells are controlled. The study, which focuses on the process by which these cells renew and increase in number, could help research to find new treatments. Researchers have found that a protein, which switches on genes to allow embryonic stem cells to self-renew, works better when the natural occurring level of the protein is reduced. It was previously thought that once levels of this protein – called Oct 4 – were reduced the numbers of new stem cells being produced would also ...

Study opens new prospects for developing new targeted therapies for breast cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: